Zofran Patent Ruling
This article was originally published in The Pink Sheet Daily
Executive Summary
Two method-of-use patents for GlaxoSmithKline's Zofran are valid and infringed by Teva's ANDA, Wilmington, Del. federal Judge Gregory Sleet ruled Aug. 20
You may also be interested in...
Teva Gains First Generic Zofran Injection Approval
FDA approval comes roughly one month ahead of patent expiration for GSK's injectable antiemetic.
Teva Gains First Generic Zofran Injection Approval
FDA approval comes roughly one month ahead of patent expiration for GSK's injectable antiemetic.
Express Scripts Anticipates Growth In 2005 From Zithromax, Zofran Generics
PBM cites anticipated contribution to growth from several first-time generics that could enter the market in 2005. Nevertheless, Express Scripts concedes that generic utilization growth will be weaker in 2005 than in other years. Subsidiary CuraScript will aid PBM's growth by converting clients that use an outside specialty pharmacy provider.